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Abstract: The Trifecta valve has externally mounted leaflets; it differs from classic internally mounted
valves (e.g., Carpentier-Edwards [C-E]). We evaluated post-implantation hemodynamics and clinical
outcomes of these bioprostheses in small aortic annuli. From January 2015 to April 2019, 490 pa-
tients who underwent aortic valve replacement (AVR) were reviewed retrospectively. Altogether,
183 patients received 19 or 21 mm diameter C-E (n = 121) or Trifecta (n = 62) prostheses. To minimize
confounding variables, we performed propensity-score matching analysis. The mean transvalvular
pressure gradient (TVPG) was significantly lower in the Trifecta than in the C-E group at discharge
(12.9 ± 4.8 vs. 15.0 ± 5.3 mmHg, p = 0.044). TVPG change over time was not significantly different
between groups (p = 0.357). Left ventricular mass index decreased postoperatively (reduction: C-E,
28.1%; Trifecta, 30.1%, p = 0.879). No late mortality, severe patient–prosthesis mismatch, moderate-
to-severe paravalvular leakage, structural valve degeneration, or valve thromboses were observed.
Freedom from valve-related events at 3 years were similar for C-E (97.9% ± 2.1%) and Trifecta
(97.7% ± 2.2%) patients (log-rank p = 0.993). Bioprosthesis design for small annuli significantly
affected TVPG immediately after AVR. However, hemodynamics over time and clinical outcomes
did not differ between the two designs.
Keywords: heart valve prosthesis implantation; hemodynamic monitoring; prosthesis design; small
aortic annulus
1. Introduction
With the growth in the elderly population, bioprosthetic valves are being increasingly
used in patients with symptomatic aortic valve disease. Bioprosthetic valves have low
thrombogenic risk and do not require continuous use of anticoagulants. Although biopros-
thetic valves have improved in durability and excellent hemodynamic performance [1],
patient–prosthesis mismatch (PPM) is a potential issue in patients undergoing aortic valve
replacement (AVR), particularly in patients with a small annulus [2]. To minimize PPM,
which is associated with worse clinical outcomes and decreased survival [3], the effective
orifice area (EOA) of the implanted prosthesis should be maximized. Supra-annular aortic
bioprostheses, such as the Carpentier-Edwards (C-E) PERIMOUNT Magna valves (Ed-
wards Lifesciences Corp, Irvine, CA, USA) and Trifecta valves (St. Jude Medical, Inc., St.
Paul, MN, USA), were introduced to counteract this issue, and both valves have optimized
EOA and low transvalvular gradients [4–6].
The Trifecta valve has a different design from that of the classic internally mounted
C-E valve, with externally mounted leaflets to maximize the valve opening. Despite these
J. Clin. Med. 2021, 10, 1063. https://doi.org/10.3390/jcm10051063 https://www.mdpi.com/journal/jcm
J. Clin. Med. 2021, 10, 1063 2 of 13
significant differences, studies comparing post-implantation hemodynamic and clinical
outcomes of these two valves are limited [6,7], and in particular, few studies have compared
these outcomes among Asian patients with a small aortic annulus [2]. Therefore, the aims
of this study were to evaluate the early hemodynamic performance of these two differently
designed valves and to review the clinical outcomes of small-sized bioprostheses in patients
undergoing AVR.
2. Materials and Methods
2.1. Study Population
Between January 2015 and April 2019, 490 consecutive patients who had undergone
AVR with a bioprosthesis were retrospectively reviewed at Severance Cardiovascular
Hospital, Yonsei University College of Medicine. Patients who had undergone sutureless
aortic valve implantation (n = 121) and received other bioprostheses (n = 32) or homografts
(n = 3) were excluded from the analysis. In addition, patients who had undergone an aortic
root enlargement procedure (n = 7), potentially affecting the hemodynamics and clinical
results, were excluded from the study. Among the remaining 327 patients, 183 patients with
a small aortic annulus had received an AVR with a 19 mm or 21 mm diameter bioprostheses
(C-E: n = 121 and Trifecta: n = 62) and were enrolled in this study.
The study procedures were performed according to the guidelines stipulated in the
Declaration of Helsinki, and the study was approved by the Institutional Review Board of
Yonsei University College of Medicine (approval number: 4-2018-0274). The need to obtain
individual informed patient consent was waived because of the retrospective nature of
the study.
2.2. Surgical Technique
AVR with a bioprosthesis was performed using median or partial upper sternotomy
with standard cardiopulmonary bypass and mild hypothermia (32 ◦C). Antegrade cold
blood cardioplegia provided myocardial protection. After excision of the diseased aortic
valve and decalcification of the annulus, the bioprosthesis type was selected according
to the surgeon’s preference. The appropriate bioprosthetic valve size was determined by
measuring the aortic annulus using a standard manufacturer’s sizer. The bioprosthesis
was implanted in the supra-annular position using non-everting mattress sutures. Post-
operatively, all patients received oral warfarin as anticoagulation treatment for the first
3 months, with a target international normalized ratio (INR) of 2.5. However, patients
who also used antiplatelet agents received anticoagulation treatments based on an INR of
2.0 (range: 1.8–2.2) to reduce the risk of bleeding.
2.3. Echocardiographic Assessment
Echocardiographic parameters, including left ventricular (LV) ejection fraction, peak
and mean transvalvular pressure gradients (TVPG), aortic valve area (AVA) or EOA, and
left ventricular mass index (LVMI), were measured according to established guidelines [8].
LV ejection fraction was assessed using the Simpson method, and the transvalvular gradi-
ents were derived from the transaortic flow using the simplified Bernoulli equation with
continuous-wave Doppler [8]. LV mass was calculated using the Devereux formula [9] and
normalized to body surface area (BSA) to obtain LVMI. The AVA or EOA was calculated
from the continuity equation by using the LV outflow tract area and the time velocity
integral. At discharge, the indexed EOA (IEOA) was calculated as EOA (information on
the type and size of each bioprosthesis was obtained from the manufacturers) divided by
the patient’s BSA. PPM was classified as moderate (0.65 < IEOA ≤ 0.85 cm2/m2) or severe
(IEOA ≤ 0.65 cm2/m2) [10].
2.4. Data Collection and Outcomes
Follow-up clinical information was obtained from the patients’ medical records or
through telephonic interview. We obtained data on cause of death, provided by Statistics
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Korea, a central organization for statistics under the Ministry of Strategy and Finance,
for the study period. The clinical mean follow-up duration was 2.5 ± 1.2 years. Patients
underwent transthoracic echocardiography by two independent experienced cardiologists
preoperatively at discharge, 1 year after surgery, and biennially thereafter if available. All
patients (100%) underwent an echocardiogram at discharge. Follow-up echocardiography
was available in 87.3% and 67.1% of the patients at 1 and 3 years, respectively. However,
assessment of in vivo EOA by echocardiogram was available in 97.9%, 85.1%, and 66.3% of
the propensity-score matched patients at each of the above time points. The echocardio-
graphic follow-up duration was 1.6 ± 0.6 years in the C-E group and 2.1 ± 0.8 years in the
Trifecta group. The study follow-up was closed in October 2019.
The primary endpoint was the hemodynamic performance (change in TVPG and LVMI)
of the bioprostheses at discharge and during the follow-up period. The secondary endpoints
were early and late adverse events (classified as events occurring ≤30 and >30 days after
AVR, respectively), overall survival, and valve-related events at the follow-up time points.
Early outcomes were defined using the Society of Thoracic Surgeons’ guidelines [11]. Oper-
ative mortality was defined as any death within 30 days after surgery, or during the same
hospital admission. “Valve-related events” were defined as a composite outcome of struc-
tural valve deterioration (SVD), pacemaker implantation, endocarditis, valve thrombosis,
severe PPM, and valve-related mortality. SVD was defined as an increase in the mean
aortic gradient by > 20 mmHg, with a concomitant decrease in EOA by >0.6 cm2 (and/or a
decrease in the Doppler velocity index > 0.15) during follow-up, leading to severe aortic
stenosis, and/or new onset or increase of intraprosthetic regurgitation causing moderate
or severe aortic regurgitation [12]. Prosthesis paravalvular regurgitation, valve thrombosis,
and endocarditis were not considered SVDs.
2.5. Statistical Analysis
Statistical analyses were performed using R software version 3.6.1 (available through
R-project online). Continuous variables are presented as the mean ± standard deviation
when normally distributed or as the median [interquartile range] when non-normally
distributed. Categorical variables are presented as absolute numbers and percentages.
Groups were compared using a Student’s t-test or Mann–Whitney U test for continuous
variables, and a chi-square test or Fisher’s exact test for categorical variables, as appropriate.
To correct for potential confounders between the groups, we performed propensity-
score matching analyses. Propensity scores were derived using a separate logistic regression
model that included patients’ demographical characteristics (i.e., age, gender, body surface
area, hypertension, diabetes, and chronic renal failure) and operative data (isolated AVR
and concomitant procedures) as shown in Table 1. Valve size, aortic cross-clamp (ACC)
time, and cardiopulmonary bypass (CPB) time were not included in the propensity model.
Propensity scores were then matched to obtain pairs of matched patients. In this study, we
adopted widely used matching methods, such as optimal matching. Discrimination and
calibration of propensity scores were assessed with C statistics and Hosmer–Lemeshow
statistics (p = 0.829 and p = 0.736), respectively. The balance of covariates between groups
was assessed by standardized mean differences with adequacy considered as < 0.2. Compar-
isons within the matched cohort were performed using a paired-sample t-test or Wilcoxon
signed-rank test for continuous variables, and a McNemar’s test for categorical variables.
After matching, mixed-effects models were used to further investigate the changes in
echocardiographic measurements over time and to account for the correlation between
repeated follow-up measurements according to the bioprosthesis type. Piecewise-linear
models, using time as a continuous measure and a random effect parameter for the patients,
were constructed with knot values at times A (preoperative) and B (from discharge up to
3 years postoperative). Interaction of valve type (group: C-E vs. Trifecta) and postoperative
time course of TVPG and LVMI were assessed. Overall survival and freedom from valve-
related events were compared using the Kaplan–Meier estimator for survival analysis and
the log-rank test. Statistical significance was defined as a 2-sided p-value < 0.05.
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(n = 47) SMD
Patient Demographics
Age (years) 73.3 ± 6.5 72.0 ± 7.9 0.180 73.5 ± 5.6 73.4 ± 4.3 0.021
Female 100 (82.6) 47 (75.8) 0.169 37 (78.7) 38 (80.9) 0.053
Body surface area (m2) 1.54 ± 0.14 1.56 ± 0.14 0.113 1.55 ± 0.12 1.55 ± 0.12 0.025
Hypertension 82 (67.8) 38 (61.3) 0.156 31 (66.0) 33 (70.2) 0.108
Diabetes mellitus 38 (31.4) 15 (24.2) 0.161 15 (31.9) 13 (27.7) 0.093
Chronic renal failure 19 (15.7) 5 (8.1) 0.238 2 (4.3) 3 (6.4) 0.095
Cerebrovascular accidents 25 (20.7) 7 (11.3) 0.258 5 (10.6) 5 (10.6) <0.001
Chronic lung disease 10 (8.3) 5 (8.1) 0.007 4 (8.5) 3 (6.4) 0.081
Peripheral artery disease 17 (14.0) 4 (6.5) 0.127 3 (6.4) 3 (6.4) <0.001
Coronary artery disease 34 (28.1) 14 (22.6) 0.393 10 (21.3) 10 (21.3) 0.121
Previous PCI 17 (14.0) 2 (3.2) 0.252 2 (4.3) 1 (2.1) <0.001
Previous cardiac surgery 14 (11.6) 4 (6.5) 0.179 1 (2.1) 2 (4.3) 0.121
Atrial fibrillation/flutter 40 (33.1) 12 (19.4) 0.315 10 (21.3) 10 (21.3) <0.001
Logistic EuroSCORE (%) 15.7 ± 16.5 12.8 ± 14.7 0.186 12.6 ± 12.2 12.4 ± 14.8 0.011
EuroSCORE II (%) 7.7 ± 12.1 4.9 ± 7.9 0.278 4.7 ± 5.3 4.8 ± 8.3 0.014
NYHA III-IV 63 (52.1) 29 (46.8) 0.106 21 (44.7) 23 (48.9) 0.094
Valve pathology
Degenerative 60 (49.6) 33 (53.2) 0.073 25 (53.2) 27 (57.4) 0.086
Bicuspid 13 (10.7) 15 (24.2) 0.360 11 (23.4) 9 (19.1) 0.104
Rheumatic 28 (23.1) 7 (11.3) 0.318 8 (17.0) 6 (12.8) 0.120
Endocarditis 10 (8.3) 4 (6.5) 0.069 2 (4.3) 2 (4.3) <0.001
Prosthetic failure 8 (6.6) 2 (3.2) 0.157 1 (2.1) 2 (4.3) 0.121
Aortic stenosis 78 (64.5) 41 (66.1) 0.035 32 (68.1) 32 (68.1) <0.001
Aortic regurgitation 16 (13.2) 12 (19.4) 0.167 7 (14.9) 8 (17.0) 0.058
Mixed aortic lesion 15 (12.4) 7 (11.3) 0.034 7 (14.9) 5 (10.6) 0.128
Operative data
Valve size b 0.292 0.529
19 mm 22 (18.2) 17 (27.4) 6 (12.8) 13 (27.7)
21 mm 99 (81.8) 45 (72.6) 41 (87.2) 34 (72.3)
Isolated AVR 38 (31.4) 32 (51.6) 0.419 22 (46.8) 25 (53.2) 0.110
Concomitant procedures
Coronary artery bypass 13 (10.7) 8 (12.9) 0.067 7 (14.9) 6 (12.8) 0.062
Mitral valve surgery 54 (44.6) 8 (12.9) 0.748 9 (19.1) 8 (17.0) 0.055
Tricuspid valve surgery 37 (30.6) 5 (8.1) 0.595 6 (12.8) 5 (10.6) 0.066
Aorta replacement 8 (6.6) 10 (16.1) 0.303 7 (14.9) 6 (12.8) 0.062
Surgical ablation 16 (13.2) 5 (8.1) 0.168 4 (8.5) 5 (10.6) 0.072
ACC time (min) b 93.1 ± 40.4 79.0 ± 27.6 0.385 81.4 ± 37.3 80.5 ± 28.9 0.027
CPB time (min) b 120.2 ± 48.2 108.7 ± 36.8 0.257 103.8 ± 41.9 110.6 ± 38.0 0.170
a Values are presented as mean ± standard deviation or n (%). b not included in the propensity model. ACC = aortic cross-clamp;
AVR = aortic valve replacement; C-E = Carpentier-Edwards; CPB = cardiopulmonary bypass; EuroSCORE = European System for Cardiac
Operative Risk Evaluation; NYHA = New York Heart Association; PCI = percutaneous coronary intervention; SMD = standardized
mean differences.
3. Results
3.1. Patient Characteristics and Operative Results
The baseline characteristics of the patients are reported in Table 1. Before matching,
the C-E group had a higher prevalence of previous percutaneous coronary intervention,
a higher EuroScore II, and fewer bicuspid-valve pathologies than the Trifecta group (all
p < 0.05). Moreover, the C-E group tended to have a higher prevalence of atrial fibrillation
(AF; p = 0.052) and rheumatic pathology than the Trifecta group (p = 0.054). After the
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application of matching, all variables were appropriately balanced and were similar in
both groups (n = 47 in each).
The 19 mm bioprosthesis was more frequently used in the Trifecta group than in the C-
E group (before matching: 27.4% vs. 18.2%, p = 0.149 and after matching: 27.7% vs. 12.8%,
p = 0.072), although this differential preference of usage was not significant between the
two groups. After risk adjustment, the distribution of surgeries, such as isolated AVR
and AVR with concomitant procedures (multiple valvular surgery and ascending aorta
replacement), was similar in both groups (Table 1).
3.2. Early and Late Clinical Outcomes
In the whole cohort, there were 5 cases of in-hospital mortality caused by bowel
perforation, pneumonia, and heart failure in the C-E group, and by brain hemorrhage in
the Trifecta group. The actuarial survival at 3 years was 94.3% ± 2.3% and 96.6% ± 2.4%
(log-rank p = 0.538) in the C-E and Trifecta groups, respectively (Figure 1A).
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prosthetic valve endocarditis, which required reoperation, at 7 months postoperatively. 
In the C-E group alone, 3 patients (2.5%) underwent pacemaker implantation and 5 pa-
tients (4.1%) had severe PPM. There were no patients with SVD in either group, and there 
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as no differ nce in early postoperative complications between th two groups
(Table 2). During the follow-up period, 1 patient in the Trifecta group expe ienced rosthetic
valve ndoc rditis, which required reoperation, at 7 months postoperatively. In the C-E
group alone, 3 patients (2.5%) underwent pacemaker implantation and 5 patients (4.1%)
had severe PPM. There were no patients with SVD in either group, and there was no
reoperation due to SVD. Only 1 patient in the C-E group developed subclinical (possible)
SVD (increase in mean TVPG of > 10 mm Hg with concomitant decrease in EOA >0.3 cm2),
compared with discharge echocardiographic assessment. Moreover, both groups had no
abnormal changes in aortic valve morphology (thickening, calcification, flail leaflets, or
pannus), impaired mobility of bioprosthetic valve leaflets, or disruptions of any valvular
components (strut/frame). Valve-related events were observed in 9 (7.4%) and 3 (4.8%)
patients receiving C-E and Trifecta, respectively. The actuarial freedom from valve-related
events at 3 years was 88.9% ± 3.8% and 94.5% ± 3.1% in the C-E and Trifecta groups,
respectively (log-rank p = 0.395; Figure 1B), and it was not significantly related to the
valve type.
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Early results
Reoperation for bleeding 8 (6.6) 3 (4.8) 0.752 1 (2.1) 1 (2.1) >0.999
Renal failure 5 (4.1) 2 (3.2) >0.999 1 (2.1) 1 (2.1) >0.999
Prolonged ventilation 9 (7.4) 4 (6.5) >0.999 2 (4.3) 3 (6.4) >0.999
Cerebrovascular events 4 (3.3) 2 (3.2) >0.999 1 (2.1) 2 (4.3) >0.999
Atrial fibrillation 20 (16.5) 11 (17.7) 0.836 9 (19.1) 8 (17.0) 0.789
Operative mortality 4 (3.3) 1 (1.6) 0.664 1 (2.1) 1 (2.1) >0.999
Late results
Infective endocarditis 0 (0) 1 (1.6) 0.339 0 (0) 1 (2.1) >0.999
Pacemaker implantation 3 (2.5) 0 (0) 0.552 1 (2.1) 0 (0) >0.999
Paravalvular leakage
Mild 3 (2.5) 1 (1.6) >0.999 1 (2.1) 1 (2.1) >0.999
Moderate–severe 0 (0) 0 (0) 0 (0) 0 (0) -
Patient–prosthesis mismatch
Moderate 22 (18.2) 11 (17.7) 0.942 6 (12.8) 7 (14.9) 0.765
Severe 5 (4.1) 0 (0) 0.169 0 (0) 0 (0) -
a Values are presented as n (%). C-E = Carpentier-Edwards; SVD = structural valve deterioration.
After matching, in-hospital mortality (2.1% vs. 2.1%; p >0.999) was similar in both
groups, and there was no late mortality. Early clinical outcomes were not different between
the two groups (Table 2). None of the patients experienced moderate-to-severe paravalvular
leakage, severe PPM, valve thrombosis, or SVD at follow-up. The incidence of moderate
PPM did not differ significantly between the two groups (C-E, 12.8% vs. Trifecta, 14.9%;
p = 0.765). In the Trifecta group, infective endocarditis was diagnosed in the same patient
as before the matching, and reoperation was required. Valve-related events occurred in
1 (2.1%) patient each from the C-E and Trifecta groups. However, time-related events
(mortality and valve-related events) for the matched cohort hardly occurred; therefore, the
Kaplan–Meier curve could not be used.
3.3. Hemodynamic Results for Matched Patients
As shown in Table 3, peak and mean TVPGs at discharge were significantly lower
in the Trifecta group than in the C-E group (24.0 ± 9.0 vs. 27.9 ± 10.4 mm Hg, p = 0.045;
12.9 ± 4.8 vs. 15.0 ± 5.3 mm Hg, p = 0.044, respectively). However, at 1 and 3 years
postoperatively, there were no significant differences between the two groups. For the
interaction of valve type and postoperative time course (Time B in Figure 2), there was no
significant effect in either the peak (p = 0.339) or mean (p = 0.553) TVPGs. This is followed
by a sustained and stable pattern of TVPG throughout the postoperative period of 3 years
in both groups (Figure 2A,B).
The Trifecta group had significantly larger theoretical IEOAs (calculated by dividing
the manufacturer’s EOA by the BSA) at discharge than that of the C-E group (1.01 ± 0.10 vs.
0.96 ± 0.08 cm2/m2, p = 0.001), but the in vivo IEOAs (EOA measured by echocardiogram)
were similar in both groups (p = 0.995). In addition, LVMI in the C-E and Trifecta groups
decreased from 137.5 ± 40.1 g/m2 and 145.3 ± 39.0 g/m2 at baseline to 98.9 ± 20.7 g/m2
and 101.6 ± 24.1 g/m2, at 3 years postoperatively, respectively (reduction rate: 28.1% and
30.1%). As shown in Figure 2C, although LVMI decreased steadily over time after surgery,
no differences were noted between the two groups (p = 0.879).
J. Clin. Med. 2021, 10, 1063 7 of 13
Table 3. Echocardiographic results of the matched patients at each time point.
Variables a Group Baseline Discharge 1-Year 3-Year p-Value * p-Value †
Peak gradient
(mmHg)
C-E 82.5 ± 32.8 27.9 ± 10.4 22.8 ± 8.3 22.8 ± 8.1
0.045 0.339Trifecta 87.6 ± 34.2 24.0 ± 9.0 23.1 ± 6.7 25.5 ± 7.1
Mean gradient
(mmHg)
C-E 50.9 ± 22.2 15.0 ± 5.3 11.9 ± 4.4 12.5 ± 4.5
0.044 0.553Trifecta 53.9 ± 23.4 12.9 ± 4.8 12.2 ± 3.6 13.7 ± 3.9
Aortic valve area
(cm2)
C-E 0.79 ± 0.24 1.71 ± 0.35 1.74 ± 0.35 1.66 ± 0.34
0.895 0.112Trifecta 0.73 ± 0.26 1.70 ± 0.36 1.65 ± 0.30 1.56 ± 0.29
Indexed EOA
(cm2/m2) b
C-E 0.51 ± 0.15 1.10 ± 0.24 1.12 ± 0.23 1.08 ± 0.24
0.995 0.097Trifecta 0.47 ± 0.18 1.11 ± 0.25 1.07 ± 0.22 1.02 ± 0.21
LVMI (g/m2)
C-E 137.5 ± 40.1 119.0 ± 34.5 100.8 ± 24.5 98.9 ± 20.7
0.275 0.879Trifecta 145.3 ± 39.0 126.5 ± 31.5 103.5 ± 26.5 101.6 ± 24.1
a Values are presented as mean ± standard deviation. b The indexed EOA was calculated by dividing the in vivo EOA, measured using
echocardiogram, by the patient’s body surface area; it was evaluated in 97.9% (n = 92/94), 85.1% (n = 80/94), and 66.3% (n = 61/92) of the
matched patients at each time point. * p-value: Baseline vs. discharge. † p-values for change from discharge to 3 years postoperatively are
based on the estimates from the mixed model. C-E = Carpentier–Edwards; EOA = effective orifice area; LVMI = left ventricular mass index.
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0.044 0.553 
Trifecta 53.9 ± 23.4 12.9 ± 4.8 12.2 ± 3.6 13.7 ± 3.9 
Aortic valve area 
(cm2) 
C-E 0.79 ± 0.24 1.71 ± 0.35 1.74 ± 0.35 1.66 ± 0.34 
0.895 0.112 
Trifecta 0.73 ± 0.26 1.70 ± 0.36 1.65 ± 0.30 1.56 ± 0.29 
Indexed EOA 
(cm2/m2) b 
C-E 0.51 ± 0.15 1.10 ± 0.24 1.12 ± 0.23 1.08 ± 0.24 
0.995 0.097 Trifecta 0.47 ± 0.18 1.11 ± 0.25 1.07 ± 0.22 1.02 ± 0.21 
LVMI (g/m2) 
C-E 137.5 ± 40.1 119.0 ± 34.5 100.8 ± 24.5 98.9 ± 20.7 
0.275 0.879 Trifecta 145.3 ± 39.0 126.5  31.5 10 .5 ± 26.5 101.6 ± 24.1 
a Values are presented as mean ± standard deviation. b The indexed EOA was calculated by dividing the in vivo EOA, 
measured using echocardiogram, by the patient’s body surface area; it was evaluated in 97.9% (n = 92/94), 85.1% (n = 80/94), 
and 66.3% (n = 61/92) of the matched patients at each time point. * p-value: Baseline vs. discharge. † p-values for change 
from discharge to 3 years postoperatively are based on the estimates from the mixed model. C-E = Carpentier–Edwards; 
EOA = effective orifice area; LVMI = left ventricular mass index. 
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and 30.1%). As shown in Figure 2C, although LVMI decreased steadily over time after 
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Figure 2. Changes in echocardiographic measurements over time for the Carpentier-Edwards (C-E) and Trifecta valves: 
(A) Peak gradient from baseline to discharge (Time A) and from immediately after surgery to 3 years postoperatively 
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Figure 2. Changes in echocardiographic measurements over time for the Carpentier-Edwards (C-E) and Trifecta valves:
(A) Peak gradient from baseline to discharge (Time A) and from immediately after surgery to 3 years postoperatively (Time
B); (B) Mean gradients following the same timeline; (C) Left ventricle mass index (LVMI). No significant time-valve effects
on gradients or LVMI were found. p-values shown for analyses from baseline to discharge (Time A) and the interaction of
the mixed model.
Similar echocardiographic findings were found when the data were stratified by valve
size for the C-E and Trifecta bioprostheses (Figure 3). p-values of the peak and mean TVPG
from baseline to discharge alone were statistically significant in patients that received the
21 mm diameter valve.
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Figure 3. istri ti of echocardiographic values for each prosthetic size: (A) The distributi n of the peak gradient;
(B) Mean gradient distribution; (C) Indexed effective orifice area (IEOA) distribution; and (D) Left ventricular mass index
(LVMI) distribution, for both prosthetic sizes (19 mm and 21 mm) in the matched patients; p-values of the peak and mean
transvalvular pressure gradients from baseline to discharge alone were statistically significant in patients that received the
21 mm diameter valve (p-value < 0.05).
4. Discussion
In the matched patients with a small aortic annulus, the Trifecta group had significantly
lower TVPG and larger theoretical IEOA at discharge than the C-E group. However, for
up to 3 years postoperatively, there was no significant difference in TVPG between the
two groups. LVMI in both groups showed a substantial and steady decrease over the
study period compared to the preoperative period, with no significant time-related changes
found between the two groups. Furthermore, no severe PPM, significant paravalvular
leakage, or valve thrombosis was identified in either groups. Before and after matching,
overall survival, and valve-related events were not significantly related to valve type.
AVR for the small aortic annulus requires implantation of a small-sized prosthesis,
which could lead to a high incidence of PPM, procedural complications, and residual
TVPG. To ensure placement of the most appropriately sized valve and to optimize the
hemodynamic results, surgeons may consider several strategies, including an AVR with
aortic root enlargement, implantation of a rapid deployment (or sutureless) valve, use of a
supra-annular valve, and different suture techniques. We focused on two bioprostheses,
which differed according to the presence of internal or external mounting of leaflets around
the strut. The C-E valve, with three pericardial leaflets, is internally mounted under a
flexible stent, whereas the Trifecta valve is an externally mounted valve with a single sheet
of pericardial tissue wrapped around a titanium stent [5]. Theoretically, the leaflets of the
Trifecta valve are able to open fully. This prevents reduction of blood flow and ensures a
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relatively larger internal diameter, which should result in a low TVPG and a large EOA
(Figure 4). It was confirmed that the 19 mm and 21 mm diameter Trifecta valves had
EOA values (provided by the manufacturers) of at least 0.1 cm2 larger than those of the
C-E valves.
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revio s st ies have shown that the Trifecta valve is beneficial in terms of achieving
lo er pressure gradients and higher EOA i mediately after surgery [6,7,13]. However,
endt et al. reported no correlations bet een these values and valve type in a multivariate
covariance analysis [6]. Tadokoro et al. showed that the early hemodynamic advantage
of the Trifecta valve lasted for up to 1 year postoperatively. Thereafter, this difference
diminished gradually over time [14]. These results are partially consistent with our findings,
showing that the differences in the TVPG between the two groups did not change over
time, with the only exception being the time immediately after surgery. Therefore, despite
performing a propensity-score matching analysis, we will need to consider patient-related
factors that could affect the hemodynamic performance, such as concomitant surgery and
preoperative characteristics, as it is difficult to explain these clinical and hemodynamic
outcomes by prosthetic design alone. Furthermore, the surgeon’s surgical experience and
the suture technique used can also affect TVPG and EOA [15].
Generally, LV mass regresses by 20–30% after AVR [16–18]. In our study, both groups
demonstrated continuous reduction in LVMI from after surgery until the last follow-up,
as compared to that before surgery (C-E: 28.1% reduction; Trifecta: 30.1% reduction). As
previously reported, a marked reduction in LV afterload following an AVR considerably
decreases LV systolic and diastolic pressures, thereby reducing mean LV pressure [18,19].
In a recent study published by Rubens et al., they reported that the Trifecta valve had
a significantly greater LV mass regression than the C-E valve (45.5 g/m2 vs. 28.3 g/m2,
p = 0.016),and improved mid-term clinical composite outcomes of readmission, congestive
heart failure, and all-cause mortality [20]. Moreover, Une et al. [21] showed that LV mass
regression in both patients with aortic stenosis (AS) and those with aortic regurgitation
(AR) occurred at a steep decline over 2 years after AVR. Vollema et al. [22] reported that LV
mass regression and changes in LV global longitudinal strain were similar despite different
preoperative LV remodeling in patients with AS and those with AR. These findings are
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consistent with our results. After matching, 15–17% of patients with AR were included
in the LV mass regression analysis; however, LVMI steadily decreased in both valves
regardless of the pathophysiology of AS and AR (from baseline to 3 year follow-up; AS,
139.2 ± 35.7 g/m2 to 100.6 ± 21.8 g/m2; AR, 152.7 ± 55.5 g/m2 to 99.2 ± 26.4 g/m2,
respectively). In our study, although it was not possible to prove the effect of valve design
on LVMI, each valve showed significantly effective hemodynamic performance in terms of
LVMI and PPM.
It is well known that PPM after AVR increases the TVPG, causes left ventricular
hypertrophy, or interferes with LV mass regression, and these effects may increase long-
term mortality and lead to a poor prognosis [19,23]. However, in the current study, none
of the patients had severe PPM, and the rate of moderate PPM was 12.8% and 14.9%
for the C-E and Trifecta groups, respectively. Interestingly, our study was performed on
Asian patients only, who tend to have a lower BSA compared to western patients. These
acceptable PPM outcomes for both valves may be due to smaller BSAs, even when EOA is
similar (our mean BSA: 1.54 m2, compared to 1.8–1.95 m2 in other studies [7,13,24]).
Moreover, some studies have reported that PPM and increasing postoperative pres-
sure gradients are associated with SVD [25,26]. Flameng et al. [26] demonstrated that
small valve size, anti-calcification treatment, and PPM were independent predictors of
SVD. Other factors, including younger age, male sex, and porcine valve, also promoted
SVD [27,28]. In fact, SVD refers to morphological abnormalities of valve leaflets associated
with hemodynamic dysfunction in our study. Although the follow-up period was short,
there was no occurrence of clinically relevant SVD, and only 1 patient who received a C-E
valve in the unmatched cohort had subclinical SVD. Subclinical changes in hemodynamic
valve function may not be noticeable, but these findings have great importance to clinicians.
The rate of SVD is < 10% at 10 years after surgical AVR; however, its incidence progressively
increases thereafter. In a study of the C-E PERIMOUNT valve in the aortic position by
Forcillo et al. [29], they reported an actuarial freedom from reoperation for prosthetic
valve dysfunction at 10 and 20 years, which were 96% ± 1% and 67% ± 4%, respectively.
Johnstone et al. [25], in their report of 12,569 patients, demonstrated that actuarial estimates
of explant due to SVD at 10 and 20 years were 1.9% and 15%. With the Trifecta aortic
bioprosthesis, the 6-year freedom from SVD and reoperation are 95% and 96%, respec-
tively [30]. However, some reports of early Trifecta failure caused by cusp tears, early
excessive pannus formation in the inflow portion, and leaflet calcification in the outflow
portion have been described [31,32]. A study by Stubeda et al. [33] showed that Trifecta
aortic valves were associated with a significantly high risk of early reoperation in patients
aged < 60 years and in patients that were current smokers. Given that the risk of early
reoperation for SVD due to multiple factors other than mechanical issue could gradually
increase, careful echocardiogram surveillance may be warranted in patients with high
postoperative TVPG and severe PPM.
Over time, reoperation in patients with bioprostheses will be required because of SVD,
and the valve-in valve transcatheter AVR is a viable option for selected patients with high
surgical risk. Coronary artery ostial obstruction during valve-in-valve implantation is a
potentially devastating complication that could cause myocardial ischemia. The externally
mounted leaflets of the Trifecta valves may increase the risk of coronary obstruction.
Furthermore, the titanium struts and rigid sewing cuff of the Trifecta may not allow its
fracture to facilitate valve-in-valve implantation. Therefore, to optimize the outcomes of
future valve-in-vale procedure in patients with Trifecta failure, the type and size of the
bioprosthesis used should be carefully selected during AVR surgery.
This study had several limitations. First, it was a non-randomized, retrospective study
performed in a single center; thus, a selection bias influencing the decision in bioprosthetic
valve choice may have existed. Given that the number of patients with a Trifecta valve
was relatively small, and the preoperative characteristics and operative procedures in
both groups were significantly different, we used a propensity-score matching analysis to
minimize statistical error. Furthermore, in our institution, Perimount Magna ease valves
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were introduced in late 2018, and Trifecta-GT is rarely used. Therefore, patients with the
most recent valves were excluded from this study. Second, this study had a short follow-up
period and a relatively small sample size, which made it difficult to make statistically robust
inferences. Nevertheless, the study has provided us with useful information by focusing on
Asian patients with smaller body sizes, on whom AVR was performed using 19 mm or 21
mm small-sized valves. Therefore, further large-scale prospective studies are necessary to
determine the effects of two differently designed valves in patients with small aortic annuli.
Third, good hemodynamics at rest may have been overestimated because during exercise,
the TVPGs may increase and PPM may become more evident. Furthermore, missing
values for the echocardiography results may have biased our findings regarding valve
hemodynamics. Especially, hemodynamic performance over time should be interpreted
with caution because only two-thirds of the patients underwent echocardiography at 3 years
after surgery, causing the data available for analysis to be limited. Finally, we compared
the two groups using the in vitro EOA provided by manufacturer values at discharge
because the patients’ hemodynamic states, such as cardiac output and ventricular function,
were not stabilized immediately after surgery, and a poor acoustic window made the
measurement of EOA by echocardiogram difficult. However, for the mixed effect model
analysis to reflect the physiological hemodynamic flow in actual patients, subsequent
echocardiographic data based on in vivo EOA was used, and those data were obtained for
97.9%, 85.1%, and 66.3% of living patients at discharge, 1 year, and 3 years after surgery,
respectively. Although echocardiography was not performed in all patients, we believe
that the results of this study were meaningful because data from a substantial number of
patients with echocardiogram data were used. Furthermore, given the effectiveness of
EOA in the prediction of PPM, a sufficient number of patients with echocardiogram data
should be examined to predict long-term outcomes.
5. Conclusions
The Trifecta valve demonstrated improved IEOA and low TVPG at discharge, com-
pared to the C-E valve, but no difference in terms of TVPG was found during the follow-up
period. Both valves also resulted in sufficient LV reverse remodeling and favorable clinical
outcomes. Although the two differently designed valves did not affect the hemodynamics
and clinical outcomes of the patients with small annuli, further large-scale studies are
needed to confirm long-term clinical outcomes.
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